10 results about "Carcinoma bladder" patented technology

The invention relates to a triple-hole paper-based three-dimensional cell culture chip as well as a preparation method and application thereof. The chip comprises a paraffin hydrophobic region and a paper-based hydrophilic region. The preparation method mainly comprises the following steps: 1) designing a mask plate; 2) cutting the mask plate by laser; and 3) preparing the triple-hole paper-based chip by hot pressing. The thickness of the chip is 100-200 [mu] m, the porous fiber structure of the paper-based material allows transportation of oxygen and waste, and a three-dimensional microenvironment for in-vivo cell growth can be simulated. Meanwhile, a transparent and liquid-tight supporting layer is fused on the lower layer of the paper-based chip, so that leakage of cells inoculated on the upper layer of the paper-based chip is avoided. The paper-based chip is embedded into a 6-pore plate, and bladder cancer cells (5637), mouse astrocytoma (U87) and human breast cancer cells (MCF-7) are inoculated in a paper-based hydrophilic region respectively. The cell compatibility of the paper-based chip and the growth behaviors of three different types of cells in three-dimensional paper fibers are investigated. It is proved that the chip can be used for researching three-dimensional construction and growth of human and mammalian cells, and the difference between three-dimensional culture and two-dimensional culture is revealed by detecting the proliferation capacity and survival rate of different cells.

This invention relates to the field of cell detection equipment technology, specifically to a detection device for bladder cancer metabolomics biomarkers. The device includes an ELISA reader, a moving stage, and well plates housed within it. It also includes a defoamer mounted on the outer wall of the ELISA reader. The defoamer comprises a fixing part, a pair of transmission parts, and a striking part and an air blowing part disposed within the fixing part. This bladder cancer metabolomics biomarker detection device, through a mechanical linkage design between the moving stage and the defoamer, uses a gear-driven toothed plate to move a dial-driven bending plate up and down, causing a striking rod to strike the well plate. Combined with synchronous airflow from the air blowing part, a protrusion pushes a piston plate within a second groove, directing airflow from the nozzle. This achieves automated removal of air bubbles from the wells before ELISA reader detection. The dual defoaming effect of striking vibration and airflow impact eliminates optical interference, ensuring the accuracy of the detection values ​​and simplifying the detection process.

This invention discloses a chimeric guide RNA integrating RNA interference and CRISPR-Cas13d and its applications. Utilizing the structural matching between shRNA and Cas13d crRNA, this invention embeds the complete Cas13d crRNA into the classic shRNA backbone, constructing a dual-pathway synergistic silencing chimeric guide RNA (SS-Rx). Experiments have demonstrated that SS-Rx possesses the dual activity of shRNA and CRISPR-Cas13d, exhibiting superior gene silencing efficiency compared to traditional RNA silencing tools, and can inhibit the proliferation, migration, and invasion of bladder cancer cells by suppressing tumor-related genes. This invention synergistically combines the advantages of RNA interference and CRISPR-Cas13d, providing an efficient and widely applicable framework for gene function research and RNA-targeted therapy, with significant economic benefits and broad application prospects.

The invention discloses a bladder tumor cell strain with squamous differentiation characteristics and application thereof, and relates to the technical field of biological medicines. Wherein the bladder tumor cell strain is selected from one of a human bladder tumor cell strain MP-MGHU3-LT, a human bladder tumor cell strain UCSD-MGHU3-LT, a human bladder tumor cell strain UCSD-RT4-LT and a mouse bladder tumor cell strain mUCMP, the bladder tumor cell strains are all preserved in the China Center for Type Culture Collection, and the preservation numbers of the bladder tumor cell strains are respectively CCTCC NO: C2025241, CCTCC NO: C2025252, CCTCC NO: C2025253 and CCTCC NO: C2025254. The bladder tumor cell strain provided by the invention has squamous differentiation characteristics, and can be applied to model construction, mechanism research and drug screening of bladder cancer with squamous differentiation characteristics.

The application relates to a bladder cancer fine typing method and system based on nucleic acid aptamer differential analysis, which comprises the following steps: incubating a sample containing bladder cancer cells through a probe package, and performing high-throughput gene sequencing on the incubated sample to obtain sequencing data; removing abnormal samples from the sequencing data to obtain nucleic acid aptamer data; standardizing the nucleic acid aptamer data to obtain standard data including a health sample group and a case sample group; selecting differential expression aptamers from the standard data; and typing a to-be-tested sample through the differential expression aptamers. The application can identify the expression difference of specific nucleic acid aptamers in bladder cancer cells, and further realizes fine typing.

There is provided the combination of Bacillus Calmette-Guérin (BCG) vaccine and β-glucan adjuvant for the treatment of a cancer characterized by the presence of protumoral T3 neutrophils in the tumour microenvironment. The β-glucan is characterized by a μ-1,3 glucose backbone. The BCG and β-glucan combination demonstrated a synergistic effect in remodeling the tumour microenvironment to resist conversion of neutrophils into the T3 phenotype. The cancer can be bladder cancer, melanoma, lung adenocarcinoma, head and neck squamous cell cancer, pancreatic adenocarcinoma, low-grade gliomas, esophageal carcinoma, and cervical squamous cell carcinoma.

The invention relates to the technical field of recombinant bacillus calmette guerin vaccines, in particular to a gene knockout attenuated granulysin / IL-12 recombinant plasmid, a recombinant bacillus calmette guerin and application. The nucleotide sequence of the recombinant plasmid is shown as SEQ ID NO: 1, and the recombinant plasmid contains IL-12 and GLS gene segments. The gene knockout attenuated granulysin / IL-12 recombinant bacillus calmette guerin vaccine contains the recombinant plasmid disclosed by the invention. The TrpD gene of the BCG is knocked out and is combined with an IL-12 / GLS double-gene eukaryotic expression system to construct a recombinant BCG strain, so that the dual functions of effect enhancement and toxicity reduction are realized, and the BCG strain is used for treating bladder cancer. The TrpD gene of the BCG is knocked out, the toxicity of the BCG is reduced, the disseminated infection risk is reduced, and the safety is improved; th1 immune imbalance is corrected, the anti-tumor effect is enhanced, tumor microenvironment Th1 type immune remodeling is induced through IL-12, and the anti-tumor effect is enhanced; a double-gene expression system is adopted, synergistic interaction is achieved, an IL-12 / GLS double-gene expression system is integrated, IL-12 regulates Th1 unbalance, and GLS directly induces tumor cell apoptosis.

GD2-specific chimeric antigen receptor effector cells for the treatment of solid tumors, which can be combined with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor. ------ The present invention relates to GD2-specific chimeric antigen receptor (GD2.CAR) effector cells for the treatment of both solid tumors, particularly extracranial GD2+ tumors (such as soft tissue sarcomas and osteosarcomas, neuroblastomas, melanomas, lung cancers, bladder cancers, and retinoblastomas) and brain tumors. Furthermore, the present invention also relates to the use of GD2.CAR gene-modified effector cells in combination with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor in the treatment of solid tumors.

The invention discloses a method, a system, equipment and a medium for identifying tumor biomarkers. The method comprises the following steps: retrieving and analyzing a TCGA database, and obtaining circRNA data sets of a target tumor sample and a healthy person sample; marking all circRNAs expressed in the target tumor sample but not expressed in the healthy sample as a first class, and marking all circRNAs expressed in both the target tumor sample and the healthy sample as a third class; screening circRNA of which the sample ratio is higher than a first preset threshold value and the average expression quantity is greater than a second preset threshold value from the first class, and marking the circRNA as a biomarker of the target tumor; screening circRNA with significant expression difference between the target tumor sample and the healthy sample from the third class, and marking the circRNA as a candidate biomarker; and screening the biomarker of the target tumor from the candidate biomarkers by adopting a feature selection technology and a deep learning algorithm. According to the invention, circRNA which can be used for early diagnosis and prognosis evaluation of bladder cancer can be accurately identified as a biomarker.

The present invention discloses biomarkers of colorectal cancer tumor border cell subpopulations and their applications in diagnosis, prevention, treatment and prognosis. The present invention also discloses a microenvironment cell map of adjacent and cancerous tissues of colorectal cancer patients, in which FAP is specifically enriched in colorectal cancer tissues. + Fibroblasts and SPP1 + The present invention also discloses FAP + Fibroblasts and SPP1 + The present invention further discloses that patients with high expression of these two proteins in bladder cancer data sets also have a lower response rate to PD-L1 treatment. The present invention also discloses FAP + Fibroblasts and SPP1 + Macrophages are also spatially localized in colorectal cancer, forming a "wall"-like tumor boundary around the tumor center, thereby preventing immune cells from entering the tumor center. These cellular characteristics and cell interaction patterns can be used to effectively diagnose, prevent, treat, and assess prognosis and survival for CRC.